ReviewNature metabolism2026
Adiposity and cancer: epidemiology, mechanisms and future perspectives.
Review in Nature metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Adiposity and cancer: systematic review and meta-analysis.Nature metabolism · 2026Pooled it
- Adiposity and cancer: epidemiology, mechanisms and future perspectives.Nature metabolism · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Excess adiposity is a major modifiable risk factor for at least 19 cancer types, and the burden of obesity-related cancer is expected to rise substantially in the coming decades. A comprehensive understanding of underlying mechanisms and precise risk associations will be critical to inform targeted prevention strategies and reduce this burden. In this Review, we examine key biological mechanisms linking adiposity and cancer, including sex hormones, hyperinsulinaemia and chronic inflammation, alongside emerging insights from omics technologies, and tumour subtype-specific associations. We also highlight priorities for future research, including imaging-based adiposity measures, integration of multi-omics approaches and expanded data collection in lower-income settings and understudied populations. Finally, we consider the potential implications of emerging obesity pharmacotherapies, which may facilitate substantial weight loss at scale.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.